Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute
Articles
Future Directions for Treatment of TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Phase 3 ASCENT Trial in mTNBC: Managing Adverse Events
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Sequencing Therapies for mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for BRCA+ mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Testing for PD-L1 Expression in mTNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for Metastatic TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Current Trials for Treatment of Early Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Emerging Data on Biomarkers in ES TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
ICI-Based Therapy in TNBC: Immune-Related Adverse Events
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Role of Immune Checkpoint Inhibitor-Based Therapy in ES TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Early Stage TNBC: Phase 3 IMpassion031 Study
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Key Trials in ICI-Based Therapy for Early Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Role of pCR in Early Stage TNBC Management
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Standard of Care for Early-Stage TNBC
Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center;Adam M. Brufsky, MD, University of Pittsburgh Cancer Institute;Sarah A. Hurvitz, MD, UCLA Jonsson Comprehensive Cancer Center;Kevin M. Kalinsky, MD, Columbia University Medical Center;Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Harvard University
October 23rd 2020Read More
Latest Updated Articles
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
%20(2)%201-Recovered-Recovered-Recovered-Recovered-Recovered.jpg?fit=crop&auto=format)
